Mutations in genes encoding the nuclear envelope proteins emerin and lamin A/C lead to a range of tissue-specific degenerative diseases. These include dilated cardiomyopathy, limb-girdle muscular dystrophy and X-linked and autosomal dominant EDMD (Emery-Dreifuss muscular dystrophy). The molecular mechanisms underlying these disorders are poorly understood; however, recent work using animal models has identified a number of signalling pathways that are altered in response to the deletion of either emerin or lamin A/C or expression of Lmna mutants found in patients with laminopathies. A distinguishing feature of patients with EDMD is the association of a dilated cardiomyopathy with conduction defects. In the present article, we describe several of the pathways altered in response to an EDMD phenotype, which are known to be key mediators of hypertrophic growth, and focus on a possible role of an emerin-β-catenin interaction in the pathogenesis of this disease.
Introduction
At the NE (nuclear envelope), multiprotein complexes exist that function to maintain nuclear integrity, regulate gene transcription and DNA replication. The composition of these protein complexes appears to be cell-type-specific, since mutations in ubiquitously expressed NE proteins lead to a group of diseases termed the laminopathies (Lmna mutations) or nuclear envelopathies (all NE proteins) [1, 2] . These disorders have diverse clinical phenotypes, ranging from skeletal and cardiac myopathies to partial lipodystrophy and premature aging syndromes and include Hutchinson-Gilford progeria, DCM (dilated cardiomyopathy) with conduction system disease, limb-girdle muscular dystrophy and EDMD (Emery-Dreifuss muscular dystrophy). Mutations in the NE proteins lamin A/C and emerin lead to AD-EDMD (autosomal dominant EDMD) and X-EDMD (X-linked EDMD) respectively [3, 4] . EDMD is characterized by progressive contractures and muscle weakness together with DCM and conduction defects. DCM is a type of hypertrophy that is characterized by a thinning of the ventricular wall and impaired contraction, frequently with an associated arrhythmia [5] . It is the unique cardiac defect of EDMD that poses the greatest threat to patient survival and often, even with the aid of a pacemaker, leads to sudden cardiac death. Furthermore, mutations in either emerin or lamin A/C can lead to cardiac defects with little or no overt skeletal myopathy [6] .
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Several mouse models of AD-EDMD and X-EDMD have been developed for studying the function of emerin and lamin A/C. These include mice that are null for either Lmna [7] or Emd [8, 9] and mice carrying Lmna missense mutations such as H222P [10, 11] , N195K [12] , L530P [13] and M371K [14] . Lmna-null mice rapidly develop skeletal muscle wasting and cardiomyopathy reminiscent of human EDMD [7] . Likewise, mice carrying the homozygous Lmna mutations H222P, N195K and M371K have a range of heart defects, including dilated heart chambers, loss of sarcomere organization and hypokinesis, which are hallmarks of DCM. In contrast, mice lacking emerin appear phenotypically normal, although some minor motor co-ordination abnormalities and mild prolongation of atrioventricular conduction time are observed [9] . In contrast with humans, where heterozygous LMNA mutations cause disease, mice heterozygous for Lmna mutations appear asymptomatic. However, it was shown recently that Lmna +/− mice express reduced levels of the protein and exhibit normal muscle pathology at birth, but develop lateonset cardiac conduction disease and DCM with no overt skeletal myopathy [15] . Animal models of EDMD have additionally provided insights into the molecular mechanisms underlying the pathogenesis of this disease. The aim of the present review is to describe the signalling pathways most likely to be associated with the EDMD phenotype.
Emerin and lamin A/C as mediators of MAPK (mitogen-activated protein kinase) signalling
Using gene-class testing based on GO (gene ontology) terms to gain insight into the overall picture of affected molecular processes in the hearts of H222P Lmna and Emd −/y mice, alterations in the expression of genes encoding proteins involved in a number of signalling pathways were identified [8, 11] . These signalling pathways included MAPK, pRb (retinoblastoma protein), MyoD, Wnt, NF-κB (nuclear factor κB)/IκB (inhibitor of NF-κB) and TGFβ (transforming growth factor β). Initiation of MAPK signalling pathways results in the sequential activation of multiple kinases that ultimately phosphorylate and activate p38, JNKs (cJun N-terminal kinases) and ERKs (extracellular-signalregulated kinases) [16] . p38, JNKs and ERKs, once activated, phosphorylate a plethora of substrates including cardiacspecific transcription factors such as GATA4 and MEF2 (myocyte-enhancing factor 2). In cardiomyocytes, signalling via growth factor receptors, GPCRs (G-protein-coupled receptors) and RTKs (receptor tyrosine kinases) leads to the activation of MAPK. Phospho-JNK and phospho-ERK1/2, mediators of hypertrophic growth [17, 18] , are increased in hearts of mice with the H222P Lmna mutation [11] , while in hearts from Emd −/y mice at 10 weeks before any signs of cardiac dysfunction, activation of ERK1/2 is evident [8] . Enhanced JNK activity is associated with the development of cardiomyopathy and conduction defects concurrent with a loss of the gap junction protein con43 (connexin-43) [19] . MEK1 (MAPK/ERK kinase 1), an activator of ERK1/2, stimulates expression of several fetal genes which are known to be up-regulated in hypertrophy such as β-MHC (β-myosin heavy chain) and ANF (atrial natriuretic factor) [20] . Both these genes are up-regulated in mouse models of EDMD [11] . Stretching forces are also mediators of ERK1/2 signalling. In this context, both lamin A/C-deficient and emerin-deficient fibroblasts, in response to mechanical strain, display impaired expression of mechanosensitive genes [21, 22] . Expression of egr-1 and iex-1 in response to mechanical stimulation is reduced, while the percentage of cells undergoing apoptosis is increased in response to prolonged mechanical stimulation. Similarly, NF-κB-regulated transcription in response to mechanical or cytokine stimulation is attenuated in Lmna −/− cells. NF-κB and EGR (early growth response), a transcription factor, have been shown to be involved in pathological cardiac hypertrophy [23, 24] . These findings suggest both emerin and lamin A/C are negative regulators of MAPK signalling; however, how the loss or mutation of an NE protein leads to activation of this signalling cascade is unclear.
pRb-MyoD signalling abnormalities in EDMD
pRb negatively regulates progression of the cell cycle from G 0 through to G 1 and into S-phase and is required for the transition of myoblasts to differentiated myotubes [25] . In proliferating cells, pRb is hyperphosphorylated by cyclin Dand E-dependent kinases and is unable to bind E2Fs, a family of transcription factors that mediate S-phase entry. Following mitogen withdrawal, cyclin D-and E-dependent kinases become inactivated, resulting in desphosphorylation of pRb, which represses cell proliferation and positively regulates cell differentiation. Additionally, in skeletal muscle, coupling of pRb with the myogenic basic helix-loop-helix transcription factor, MyoD, induces myogenic gene expression and cellcycle arrest. pRb is a binding partner of both lamin A/C [26] and LAP2α (lamina-associated polypeptide 2α) [27] . LAP2α is a member of the LAP2 family of nucleoproteins and is a soluble nucleoplasmic protein [28] . Nucleoplasmic LAP2α-lamin A/C complexes bind hypophosphorylated pRb and are thought to play a role in maintaining E2F in a repressed state. Expression of components of the pRb-MyoD signalling cascade are disrupted, not only in animal models of EDMD, but also in AD-EDMD and X-EDMD human muscle. Bakay et al. [29] used expression profiling on human muscle biopsies to develop a transcriptional model for downstream consequences of LMNA and EMD mutations. Ultimately, it was shown that, in both forms of EDMD, interactions between the NE and the pRb-MyoD pathway fail at the point of myoblast exit from the cell cycle leading to a block in myotube differentiation. CBP [CREB (cAMP-response-element-binding protein)-binding protein] is the key acetylase that is transferred from pRb to MyoD during myoblast/myotube transition. Several proteins, including CBP, NAP1L1 (nucleosome assembly protein 1-like protein 1) and CRI-1 [CBP/EP300 (E1A-binding protein 300) inhibitory protein 1], which are all involved in the regulation of pRb-MyoDmediated differentiation, exhibit increased expression in muscle containing EMD and LMNA mutations. CRI-1 is an inhibitor of CBP, which controls the timing of acetylase activity, while NAP1L1 is a protein that binds acetylated histones and serves as a chaperone to open up chromatin on downstream targets of MyoD/CBP. In a microarray analysis of regenerating muscle from Emd-and Lmna-null gastrocnemius muscle, perturbation to the pRb-MyoD pathway was apparent, but differences between the two mouse models were observed [30] . On day 3 of muscle regeneration, increased expression of Cbp, Nap1L1 and Cri-1 mRNA was observed in Emd −/y , but not Lmna −/− muscle, whereas pRb was up-regulated on day 4 in muscle from Lmna −/− similarly to pRb expression on day 3 in Emd −/y muscle. In addition, LAP2 mRNA was increased in Lmna −/− , but not Emd −/y muscle. This is consistent with LAP2α being a lamin A-binding partner and, furthermore, a mutation in LAP2α that interferes with lamin A binding causes DCM [31] . How LAP2α-lamin A/C complexes regulate pRb is unclear. An interaction between the LAP2α-lamin A/C-emerin complex and pRb at the NE may regulate the stability and/or post-translational modification of pRb. This would sequester pRb away from kinases and/or transcriptional targets, favouring cell proliferation. Therefore, in cells lacking emerin or lamin A/C, inactivation of pRb is perturbed, leading to a delay in cell differentiation.
Are there other signalling pathways involved in X-EDMD pathogenesis?
Although the above findings provide an insight into the molecular mechanisms underlying EDMD, further work is required to decipher the precise details of these pathways, especially as there are clearly subtle differences between AD-EDMD and X-EDMD. For the remainder of this review, we will focus on emerin and its interaction with several binding partners to propose the involvement of additional signalling pathways in the development of X-EDMD. Emerin binds either directly or indirectly to a plethora of proteins, including the transcriptional repressors GCL (germ cell-less) and Btf (a death-promoting transcriptional repressor), an RNA-splicing associated factor, YT521-B, the inner nuclear membrane isoforms of nesprins-1 and -2, Man1, F-actin (filamentous actin), nuclear lamins A/C and B, Lmo7 and β-catenin [1, [32] [33] [34] . Nesprin-1 and -2 have been implicated in the pathogenesis of EDMD [35] , while genomic deletion of 800 kb of Lmo7 plus eight exons of a neighbouring gene, UCHL3 (Lmo7 800), causes muscle degeneration in mice [36] . Lmo7 is a nuclear shuttling protein and additionally locates to the adherens junction in HeLa cells [32] . Knockdown of emerin leads to significantly reduced nuclear Lmo7, while reduced Lmo7 expression results in decreased Emd mRNA levels [32] . In a microarray on HeLa cells knocked down for Lmo7, genes encoding CBP, NAP1L1 and Rbl2 (retinoblastoma-like 2, also known as p130) were altered, as observed with mouse models for EDMD. Like Lmo7, β-catenin is a nuclear shuttling protein and localizes to the cytoplasmic side of the plasma membrane. The emerin-β-catenin interaction has only been studied in HEK-293 (human embryonic kidney) cells [33] . In these cells, overexpression of emerin inhibits β-catenin signalling by preventing its nuclear accumulation. Consistently, Emd −/− fibroblasts have a rapid growth phenotype; however, unlike Lmna −/− fibroblasts, the expression and phosphorylation of pRb is unaffected, and autostimulatory growth arises through the activation of β-catenin. These findings are particularly pertinent towards the understanding of the heart abnormality in EDMD, since, many years ago, Cartegni et al. [37] demonstrated that emerin additionally resides at the ICD (intercalated disc), a specialized plasma membrane region that mediates electrical and mechanical coupling between adjacent cardiomyocytes. β-Catenin is a known component of the ICD where it specifically localizes to the adherens junction. Emerin co-localizes with vinculin and cadherin in cultured rat cardiomyocytes, and electron-microscopic immunohistochemistry on ultrathin frozen sections of human heart have confirmed that emerin is also a part of the adherens junctions in the heart. Although no subsequent publication has confirmed these findings, it is interesting to note that emerin-β-catenin protein complexes exist and may play a role in the development of the cardiomyopathy seen in EDMD.
β-Catenin signalling in the heart
To propose a role for emerin-β-catenin, we first summarize the known functions of β-catenin in the heart. β-Catenin is a key mediator of early heart development and is required for both physiological and pathological hypertrophic remodelling [38, 39] . Three types of cell-cell contact exist at the ICD: desmosomes and adherens junctions anchor the ICD to the myofibrils, and gap junctions mediate electrical coupling. In an animal model of DCM, cardiomyocytes from the MLP (muscle LIM protein)-null mouse revealed alterations in the molecular composition of the ICD, including up-regulation of α-and β-catenin [5, 40] . Similarly, mutations in components of the ICD such as plakophilin-2 [41] lead to arrhythmogenic right ventricular cardiomyopathy. In hearts of patients with inherited cardiac hypertrophy and heart samples of experimental hypertrophy, β-catenin protein levels at the ICD are increased, while its nuclear accumulation is reduced [42] . Furthermore, deletion of the ICD protein, mXinα, a known binding partner of β-catenin, in mice results in hypertrophic and fibrotic hearts, indicative of cardiomyopathy [43] . At the plasma membrane/ICD, β-catenin is thought to be stabilized through interactions with cadherins and F-actin. The stability of β-catenin is dependent upon its cellular localization. When in the cytoplasm, β-catenin is targeted for destruction via a complex of APC (adenomatous polyposis coli), axin and GSK-3β (glycogen synthase kinase 3β), whereby CK1 and GSK-3β phosphorylate β-catenin, leading to its ubiquitination and ultimate proteasomal degradation. Inhibition of this destruction complex results in translocation of β-catenin to the nucleus, where, through interactions with the transcription factor Tcf (T-cell factor)/Lef-1 (lymphoid enhancer factor 1), it displaces members of the Groucho family of transcriptional repressors and activates transcription of specific target genes. In proliferating cells, stabilization of β-catenin favours cell proliferation over differentiation. However, what is less clear is how β-catenin stability and thus activity is regulated in fully differentiated cells such as cardiomyocytes. Agonists such as phenylephrine and endothelin 1 induce a biphasic pattern of β-catenin stabilization that is independent of the Wnt pathway. Instead, GSK-3β was shown to be phosphorylated on Ser 9 by Akt, inhibiting its activity leading to hypertrophic growth of cardiomyocytes [44] . Interestingly, in failing human hearts, Akt is activated, while GSK-3β is inhibited and phosphorylated on Ser 9 [45] . The inhibition of GSK-3β activity is required for cardiac hypertrophy induced by pressure overload [44, 46] . Expression of a stabilized β-catenin in cardiomyocytes and cardiac fibroblasts induces the expression of genes involved in the hypertrophic response such as survivin, Bcl-2, cyclin D1 and cyclin E2 [47] , whereas inhibition of GSK-3β leads to β-catenin translocation, where it induces transcription of con43 [48] . Up-regulation of con43, together with accumulation of β-catenin at the ICD in hypertrophic myocytes enhances mechanical and electrical connectivity during the initial stages of hypertrophic remodelling [42] . Chronic pressure overload displaces β-catenin from the ICD and subsequently leads to reduced con43 expression, consistent with myocyte disorganization and decreased mechanical and electrical coupling observed in congestive heart failure. Interestingly, in the lamin A/C-N195K mouse model of DCM-CD1 (DCM with conduction system disease), con43 is mislocalized in both atria and ventricles [12] . Mutant mice nuclei showed herniations and had a loss of emerin from the NE. These mice display periods of extreme bradycardia and a variety of conduction defects. The above evidence implicates disrupted con43 expression arising from aberrant β-catenin signalling as a possible mechanism of generating the cardiac conduction defect observed in EDMD.
A link between emerin and β-catenin in the heart?
It is reasonable to assume a role for emerin in the regulation of β-catenin in the heart. Emerin co-localizes with β-catenin in cardiomyocytes and binds to β-catenin, at least in fibroblasts. Analogous to emerin's function as a negative regulator of β-catenin-mediated cell proliferation, it could be hypothesized that, in non-cycling cardiomyocytes, emerin not only influences the export of β-catenin from the nucleus, but also binds and sequesters β-catenin at the ICDs. Consistent with this, emerin is a known binding partner of F-actin [49] , and a cDNA microarray of X-EDMD patient fibroblasts revealed an increase in both cadherin and α-catenin mRNA expression [50] . It is possible that, in cardiomyocytes of patients with X-EDMD, emerin's interaction with β-catenin is perturbed, resulting in increased β-catenin signalling and activation of hypertrophy-mediated transcription targets. Although a DCM, as opposed to hypertrophy, is associated with EDMD, it is likely that mechanisms/signalling pathways involved overlap. Indeed, the above findings clearly show a role for β-catenin and other signalling pathways in both DCM and hypertrophy.
Summary
Our understanding of the signalling pathways involved in the pathogenesis of EDMD has improved with the generation of several mouse models. Although AD-EDMD and X-EDMD share common molecular signatures, it is becoming apparent that several signalling cascades contribute to the development of these disorders. Which pathways are affected is likely to dictate the phenotype and severity of the EDMD. For example, perturbation to the pRb-MyoD pathway is likely to have an impact predominately on the development of skeletal myopathy, disruption to emerin-β-catenin could lead to the development of DCM, and alterations in MAPK signalling would result in both skeletal and cardiac defects. Deciphering the specific contribution of these signalling pathways is key to the development of therapeutic strategies. 
